Respiratory Infections

In these patient encounters, a deep cough as a symptom raised concerns around pneumonia and may have prompted prescription of antimicrobials, but did not show a resolution of symptoms sooner.

The origins of the recent H5N1 (avian flu) case in Texas remain unknown, but a researcher offers insights into transmission between animals and humans, the likelihood of more cases, vaccine availability, and treatment.

Community acquired pneumonia is often inappropriately diagnosed in hospital admissions, particularly among older adults with dementia, and can lead to in-hospital antibiotic-associated adverse events, such as Clostridioides difficile.

The case was confirmed in Texas and the person was in contact with cows. CDC says the risk for infection remains low.

A new strategy for universal infant immunization in the 2023-2024 RSV season faces implementation and medication access barriers.

Patients hospitalized for suspected community-acquired pneumonia received targeted treatment more quickly with PCR testing than with culture-based diagnostics.

Phase 2 study for the investigational antiviral, ZSP1273 (onradivir), demonstrated safety and efficacy in reducing the time to resolution of symptoms in a multicenter trial.

Group A streptococcal infections outbreak nearly doubles fatalities from the previous year.

Though more research is needed to determine reasons for the association, a study published in JAMA Network revealed the 2021-2022 influenza season was associated with a significantly higher household transmission risk compared to pre-pandemic seasons.

Results of a study by Yan Xie and colleagues highlight the severe impact of COVID-19, with higher death rates, increased risks of long-term complications, and greater infectivity compared to seasonal influenza.

In 43 of 154 school weeks, air samples were positive for influenza A virus (IAV) while SARS-CoV-2 was positive in air samples in 101 of 154 school weeks.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

The company, RNAimmune, got the ok from the FDA for its vaccine, RV-1770.

The company’s investigational V116 vaccine covers 21 serotypes, and if approved, it would be the first pneumococcal conjugate vaccine specifically designed for adults.

The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.

Investigational 24-valent pneumococcal conjugate vaccine developed on cell-free protein synthesis platform is first to broaden coverage without reduced immunogenicity.

The unprecedented demand for the pediatric RSV immunization, nirsevimab-alip, has resulted in a dramatic uptake in production.

Amikacin inhaled once daily for 3 days reduced risk of developing ventilator-associated pneumonia in placebo-controlled trial in critically ill.

Last year was the fourth season to be classified as high severity since the 2009 influenza A(H1N1) pandemic.

Topline data results from the company’s phase 3 trial, STRIDE-3, were announced and will be presented at the World Vaccine Congress West Coast.

Overall, the study authors concluded that the immunogenicity of QIV and TIV was similar for common influenza ingredients for children aged 6 to 35 months.

The federal agency was made aware some health care providers had administered the full single dose vial of the vaccine, which contains “notably more” volume than the 0.25 mL volume indicated for children aged 6 months to 11 years.

George Sakoulas, MD, highlights persistent unmet needs in managing CAP and key takeways from ID week 2023.

An expert in infectious diseases comments on multidrug-resistant pathogens such as pneumococcus in CAP, and shares thoughts on balancing antimicrobial stewardship with the pharmacoeconomics of antimicrobial therapies in CAP.

This discussion revolves around diagnostics for viruses and best practices and challenges.

Two RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.

Dr George Sakoulas shares strategies for selecting single and combination therapy when dealing with empiric vs focused treatment regimens for CAP and discusses clinical considerations for elderly patients hospitalized with CAP.

George Sakoulas, MD, provides insight on the burden on the healthcare community of community acquired pneumonia (CAP) and the influence of geography and seasonal variations on CAP.

A new study that went beyond the current standard of testing for the respiratory virus resulted in greater incidence rates and a truer accounting of case loads.

The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.